Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Study findings on breast cancer are outlined in reports from C.D. Britten and colleagues
May 7th, 2009
"This phase I/II trial was conducted to determine the toxicities, recommended dose, pharmocokinetics, and response rate of erlotinib plus trostuzumob in metastatic HER2+ breast cancer. In phase I, sequential groups of patients with unlimited previous treatment received erlotinib at dose levels of 50, 100, and 150 mg plus standard dose weekly trastuzumab," scientists in the United States report. "In phase II, only patients with no previous chemotherapy or trastuzumab in the metastatic setting were allowed. The combination was well tolerated among the 16 patients enrolled in phase I, and the recommended phase II dose of erlotinib was initially set at 150 mg. After an...
Source: Women's Health Weekly (2009-05-07)
|
